Asia Pacific Human Milk Oligosaccharides Market Size, Share & Industry Trends Analysis Report By Application, By Type (2'FL, 3'FL, 3'SL, and 6'SL), By Concentration (Neutral, and Acidic), By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Human Milk Oligosaccharides Market would witness market growth of 23.6% CAGR during the forecast period (2023-2030).

HMOs are intrinsic components that can manipulate the gut microbiota by supplying an energy source for beneficial intestinal microbiota and potentially acting as decoy molecules to inactivate pathogens on mucosal surfaces, resulting in improved host health. Health-promoting oligosaccharides are in high demand, as the significance of the gut microbiota in human health has been revealed. The rules governing the implementation of HMOs differ depending on where a person lives. Different countries have different regulations governing novel foods and foods with health claims.

Major factors driving the demand for HMOs include lifestyle improvement and a rise in concerns about health & wellness. Furthermore, HMOs in food supplements and functional food and beverage products can aid in treating specific disorders and high-risk health conditions, a key driving force of the market. This has created a market opportunity. However, high costs associated with the product are expected to challenge the market's growth during the market forecast.

Chinese consumers are increasingly aware of the significance of maternal health. HMOs naturally occur in human breast milk, playing a crucial role in developing the infant's immune system and gut microbiome. Maternal nutrition products with added HMOs aim to provide additional support for breastfeeding mothers, potentially enhancing the composition of their breast milk. The increasing affluence and urbanization in China influence consumer lifestyles and dietary preferences. The factors mentioned above will propel market growth in this region.

The China market dominated the Asia Pacific Human Milk Oligosaccharides Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $134,805.5 Thousand by 2030. The Japan market is registering a CAGR of 22.8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 24.3% during (2023 - 2030).

Based on Application, the market is segmented into Infant Formula, Functional Food & Beverages, Food Supplements, and Others (Clinical Nutrition & Pharmaceuticals). Based on Type, the market is segmented into 2'FL, 3'FL, 3'SL, and 6'SL. Based on Concentration, the market is segmented into Neutral, and Acidic. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia & New Zealand, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke DSM N.V., BASF SE, Chr. Hansen Holding A/S, DuPont de Nemours, Inc., Nestle S.A, Inbiose NV, Biosynth AG, Abbott Laboratories, Royal FrieslandCampina N.V. and Dextra Laboratories Ltd (ICE S.p.A).

Scope of the Study

Market Segments Covered in the Report:

By Application

• Infant Formula
• Functional Food & Beverages
• Food Supplements
• Others (Clinical Nutrition & Pharmaceuticals)

By Type

• 2'FL
• 3'FL
• 3'SL
• 6'SL

By Concentration

• Neutral
• Acidic

By Country

• China
• Japan
• India
• South Korea
• Australia
• New Zealand
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Koninklijke DSM N.V.
• BASF SE
• Chr.Hansen Holding A/S
• DuPont de Nemours, Inc.
• Nestle S.A
• Inbiose NV
• Biosynth AG
• Abbott Laboratories
• Royal FrieslandCampina N.V.
• Dextra Laboratories Ltd (ICE S.p.A)

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free